Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurometrix Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
NURO
Nasdaq
3841
https://www.neurometrix.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurometrix Inc
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
- Mar 14th, 2024 1:00 pm
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
- Mar 13th, 2024 1:00 pm
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
- Mar 12th, 2024 12:00 pm
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
- Mar 8th, 2024 4:15 pm
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
- Mar 4th, 2024 1:00 pm
NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)
- Feb 24th, 2024 1:46 pm
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:23 pm
Q4 2023 NeuroMetrix Inc Earnings Call
- Feb 23rd, 2024 3:28 am
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
- Feb 22nd, 2024 12:00 pm
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
- Feb 15th, 2024 2:00 pm
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
- Feb 13th, 2024 2:00 pm
Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now
- Jan 9th, 2024 12:00 pm
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
- Jan 8th, 2024 2:43 pm
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
- Dec 12th, 2023 2:00 pm
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Dec 5th, 2023 2:00 pm
NeuroMetrix Announces One-for-Eight Reverse Stock Split
- Nov 20th, 2023 2:00 pm
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now
- Oct 31st, 2023 11:00 am
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
- Oct 30th, 2023 1:00 pm
NeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call Transcript
- Oct 28th, 2023 1:43 pm
Q3 2023 NeuroMetrix Inc Earnings Call
- Oct 27th, 2023 3:45 am
Scroll